In hyperinflammatory syndromes like COVID-19, PTIC administration decreases the M1 subset, chemokines, and growth factors associated with STAT-1, improving the acute phase of the infection and avoiding long COVID-19. The gene discussed is STAT1; the disease is COVID-19.